Faron Initiates Phase 2 Part of BEXMAB Study
Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS - MDS patients who have failed prior HMA therapy selected as first indication to advance into Phase 2 - 3 mg/kg and 6 mg/kg doses selected in accordance with FDA’s Project Optimus initiative guidance - Phase 2 part of the study will recruit 32 HMA-failed MDS patients for 1:1 dose randomization with possible data release after 20 patients have received more than two treatment cycles
Nordic energy company Gasum is delivering a cargo of liquefied natural gas (LNG) to the Inkoo floating storage regasification unit (FSRU). The cargo arrived on Sunday 5 November and unloading has been started. At the FSRU the LNG is regasified and fed into the Finnish gas pipeline grid.
This is the second LNG cargo Gasum has delivered to the Inkoo FRSU since the Balticconnector gas pipeline between Finland and Estonia suffered a rupture and was shut down in early October. Repair of the pipeline is expected to take at least five months. In the meantime, all Finnish natural gas demand must
